Compare AIRI & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRI | XCUR |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3M | 13.7M |
| IPO Year | 2013 | 2017 |
| Metric | AIRI | XCUR |
|---|---|---|
| Price | $2.58 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.0K | ★ 40.1K |
| Earning Date | 05-14-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.39 | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $47,921,000.00 | N/A |
| Revenue This Year | $6.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.30 | $1.05 |
| 52 Week High | $3.95 | $9.48 |
| Indicator | AIRI | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $2.79 | N/A |
| Average True Range (ATR) | 0.09 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 47.37 | 0.00 |
Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.